Neugenesis' Intellectual Property is well protected as illustrated in the current patent portfolio that consists of the following families of patents and patent pending:

Vaccine Production

PCT/US2005/037249 (WO/2006/044796)
National phase in 13 countries and the European Patent Convention

Expression of Monoclonal Antibodies and other Complex Proteins

Heterologous dimeric proteins produced in heterokaryons
US Patent 5,643,745
Australia Patent 679,349
Europe EP 0 743 986 B1 (18 countries)
Korea 330038
Japan Pending
Canada Pending

Product Improvement Technology

Reagents and methods for diversification of DNA
US Patent 6,232,112

Methods for in vivo diversification of single genes
US Patent 7,323,299

Combinatorial Biology

Methods and compositions for combinatorial-based discovery of new multimeric molecules
US Patent 5,683,899
New Zealand 333,684

Combinatorial metabolic libraries
US Patent 6,268,140

Expression and Screening

Neurospora Expression System
US Patent 5,695,965

Light-regulated promoters for production of heterologous proteins in filamentous fungi
US Patent 5,741,665
Australia 700399

Production of heterologous peptides
US Patent 5,834,191

Neurospora hosts for the production of recombinant proteins, and methods for producing same
US Patent 5,776,730
Singapore 98033681
Australia 721,592

Exploitation of the cellulase enzyme complex of Neurospora
US Patent 5,995,270